American CryoStem Announces Completion of Patient Recruitment for its Post-Concussion Syndrome (PCS) ATCELL(TM) Phase I Clinical Trial

December 22, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / December 22, 2021 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced today that its clinical study team has completed recruiting subjects for its Investigational New Drug (IND) Phase I Clinical Trial for Post-concussion syndrome. The singe site, multi-dosage blinded study is being conducted by...

Read more

Apollo Endosurgery Announces New $100 Million Senior Secured Term Loan Facility from Innovatus Capital Partners, LLC

December 21, 2021 4:50 PM

$35 million funded at close to refinance existing debt, extend maturity and lower interest expenseAdditional borrowing capacity provides minimally dilutive growth capital and strategic flexibilityAUSTIN, TX / ACCESSWIRE / December 21, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it has entered into a debt financing...

Read more

RepliCel Terminates License Agreement with Shiseido

December 21, 2021 11:10 AM

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today that the dispute between Shiseido and RepliCel has led to the Company electing to terminate the license agreement with Shiseido. The Company's decision is a legal step in its pursuit of a resolution of its...

Read more

Viewpoint Molecular Targeting(R) Presents Preclinical Data from VMT-𝛼-NET, Theranostic in Development for the Treatment and Diagnosis of Neuroendocrine Tumors, at the Pacifichem 2021 Congress

December 21, 2021 9:00 AM

Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumorsPreclinical data of VMT-𝛼-NET demonstrated to significantly improve cell binding, tumor accumulation/retention and renal clearance of an SSTN analogVMT-𝛼-NET currently in a Phase 1 imaging study to be followed by Phase 1/2a therapy study for the treatment of neuroendocrine tumors (NETs) being conducted at the University of IowaCORALVILLE, IA /...

Read more

BioInvent Moves to NASDAQ Stockholm’s Mid Cap Segment

December 20, 2021 3:20 AM

LUND, SWEDEN / ACCESSWIRE / December 20, 2021 / BioInvent International (STO:BINV)Lund, Sweden - December 20, 2021 - BioInvent International AB ("BioInvent") (NASDAQ Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the company will be moved to the Mid Cap segment on Nasdaq Stockholm from January 3, 2022....

Read more

Hemogenyx Pharmaceuticals PLC Announces Hemo-CAR-T partnership with WuXi ATU

December 20, 2021 2:00 AM

Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programmeLONDON, UK / ACCESSWIRE / December 20, 2021 / Hemogenyx Pharmaceuticals will leverage WuXi Advanced Therapies' ("WuXi ATU") plasmid and lentiviral vector manufacturing platforms, including integrated testing, to accelerate HEMO-CAR-T programme for acute myeloid leukaemia ("AML") toward phase I clinical trials.Hemogenyx...

Read more

BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab

December 17, 2021 1:15 PM

LUND, SE / ACCESSWIRE / December 17, 2021 / BioInvent International (STO:BINV)Partial response in metastatic uveal melanoma, a difficult-to-treat indicationMarkedly improvement of stage IV sarcomaBioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces positive early data from the...

Read more

Oncology Pharma Meeting Towards Future Developments

December 17, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. ("The Company") conducted a meeting with the Board of Directors, executives, and Scientific Advisory Board members along with legal counsel, which shared updates on progress made towards the development of the Company's licensed products. This marked progress towards pursuing its primary goal of the Co-Development plan to bring new...

Read more

Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.

December 16, 2021 2:45 PM

KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has entered into an advertising and media agreement (the "Contract") for media buys and digital marketing with SRAX, Inc. ("SRAX")."Lexaria is pleased to be working with SRAX to inform and engage a broad investor community in this significant, year-long...

Read more

M2Bio Director of Health and Fitness Rob Simbowe Visits Zambia and Hosts Vulnerable Youth Symposium

December 16, 2021 10:00 AM

CAPE TOWN, SA / ACCESSWIRE / December 16, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:M2Bio Sciences is pleased to announce its Director of Health and Fitness, Brand Ambassador, and MMA Champion Rob Simbowe (AKA Black Tiger) visited Zambia and hosted the Vulnerable Youth Program and...

Read more

Vero Diagnostics Lab Launches Ultra-Rapid Covid-19 PCR Testing in Los Angeles

December 16, 2021 10:00 AM

Market's fastest PCR test to provide results to thousands per day, with results in as little as one hourLOS ANGELES, CA / ACCESSWIRE / December 16, 2021 / Vero Diagnostics, a CLIA high complexity & CAP certified, state-of-the-art laboratory, today announced the launch of the Baebies® FINDER® 1.5 ultra-rapid SARS-CoV-2 RT-PCR testing platform to Vero Diagnostics customers in Los Angeles.Ultra-rapid RT-PCR testing instruments installed...

Read more

Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results

December 15, 2021 5:30 PM

RICHMOND HILL, ON / ACCESSWIRE / December 15, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 first quarter results for the period ending October 31, 2021.OVERVIEWThe Company reported a net loss and total comprehensive loss for the...

Read more

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"

December 15, 2021 8:05 AM

LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / December 15, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications, on the mechanism of action of 4-1BB targeting bispecific antibodies. Nature Communications is an open access, multidisciplinary journal dedicated to publishing...

Read more

Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion

December 14, 2021 11:50 AM

KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week.Formal hospital and ethics board approvals for human clinical study HYPER-H21-3 had been received in March. Study HYPER-H21-3 used a placebo-controlled...

Read more

CB Scientific, Inc. Enters Beta-testing Phase for Its Updated Proprietary My-Cam Cardiac Event Monitor

December 14, 2021 6:00 AM

Updates to provide device improvements while maintaining the innovative core-functionality of CBSC's state-of-the-art cardiac event monitorESCONDIDO, CA / ACCESSWIRE / December 14, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced today that the company has entered the Beta testing phase for its updated My-Cam cardiac event monitoring device. The updated design provides improved power consumption, enhanced lead wire...

Read more

Helix BioPharma Corp. Extends Period to Exercise Warrants

December 13, 2021 6:25 PM

RICHMOND HILL, ON / ACCESSWIRE / December 14, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it is extending the exercise period of a total of 1,520,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties, for a period of two years...

Read more

Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T pre-IND Meeting Request

December 13, 2021 4:20 AM

LONDON, UK / ACCESSWIRE / December 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce significant progress in relation to moving its lead product candidate Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") toward clinical trials. The Company has applied for a pre-Investigational New Drug ("PIND") application meeting with the...

Read more

BioInvent’s Latest NHL Data at ASH Show Increased and Sustained Responses to BI-1206 in Relapsed Patients

December 11, 2021 5:45 PM

Objective response rate (ORR) 67% and disease control rate (DCR) 78% in Follicular lymphomaComplete responses lasting beyond 18, 24 and 36 monthsLUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces updated positive interim...

Read more

BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China

December 10, 2021 7:15 AM

LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), China's medical product regulator, has approved a Clinical Trial Application...

Read more

Helix Biopharma Corp. Announces Fiscal 2021 Year-End Results

December 9, 2021 5:45 PM

RICHMOND HILL, ON / ACCESSWIRE / December 9, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the 2021 fiscal year ended July 31, 2021.OVERVIEWThe Company reported a net loss and total comprehensive loss of $8,038,000 or $0.06...

Read more